Tech Company Financing Transactions
Volastra Therapeutics Funding Round
Volastra Therapeutics closed a $12 million Seed venture capital round on 4/7/2021. Investors included Arch Venture Partners, Catalio Capital Management and DROIA.
Transaction Overview
Company Name
Announced On
4/7/2021
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Seed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1361 Amsterdam Ave. 520
New York, NY 10027
USA
New York, NY 10027
USA
Phone
Website
Email Address
Overview
Volastra Therapeutics is pioneering novel approaches to halt or prevent cancer metastasis, one of the major unsolved challenges in cancer treatment. Co-founders Lewis Cantley, Ph.D., Olivier Elemento, Ph.D. and Samuel Bakhoum, M.D., Ph.D., made seminal discoveries about the role of chromosomal instability in driving cancer spread.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charles Hugh-Jones
Chief Scientific Officer
Michael Su
Vice President
Rumin Zhang
VP - Operations
Diane Tager
Browse more venture capital transactions:
Prev: 4/7/2021: OneStream Software venture capital transaction
Next: 4/7/2021: Bartesian venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs